Dr. Brian Dixon serves as Venture Partner at Elm Street Ventures. He also serves as the Chief Executive Officer of BioRelix, Inc. Prior to joining BioRelix in October 2007, Dr. Dixon served as Vice President with Bayer HealthCare in West Haven Connecticut. In that position, he led a multi-disciplinary organization of up to 130 employees that delivered state-of-the-art expertise in oncology biomarker discovery, new lead discovery, research drug formulation, pharmacokinetics and drug metabolism to Bayer's global R&D business. In addition, he held leadership roles in R&D licensing initiatives, strategic alliances and cross divisional collaborations in translational medicine. From 1998 to 2001, Dr. Dixon directed Bayer drug discovery efforts in both the Osteoporosis and Oncology therapeutic areas. He serves as a Director of BioRelix, Inc. Dr. Dixon was an undergraduate at the University of Michigan. He received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and completed post-doctoral training at Harvard University.
Boehringer Ingelheim Venture Fund is the corporate venture capital arm of Boehringer Ingelheim. The firm invests in companies operating in the oncology, biologics, genetherapy, therapeutics and healthcare sectors. It is based in Ingelheim am Rhein, Germany and was founded in 2010.
P. Bart Stephens is a Co-Founder and serves as Managing Partner at Stephens Investment Management. He is also a Co-Founder and serves as a Managing Partner at Blockchain Capital. He is the General Partner of Crypto Currency Partners funds. Bart Stephens has also been a Managing Partner of Stephens Investment Management, LLC (SIM). Stephens Investment Management is a family owned and operated hedge fund and venture capital firm. Bart and his brother and Co-Founder Brad invented the term and pioneered "Nanocap" investing - venture capital style investing in the public markets focused on sub micro-cap equities. Bart has a background as both an operating entrepreneur and a venture capitalist. Prior to co-founding SIM, Bart was Executive Vice President, Venture Capital for Ivanhoe Capital Corporation (ICC), an international investment firm. Before joining ICC, Bart was a founding investor and Head of Corporate & Business development for Oncology.com. Oncology.com grew to become the internet's largest cancer related web site before being sold to Pharmacia (now Pfizer) in 2001. Prior to Oncology.com, Bart spent more than two years with E*TRADE, an early internet innovator in online financial services. While at E*TRADE, he held senior positions focused on product marketing, business development and corporate development.Bart earned a BA degree in Political Science from Princeton University in 1997. While at Princeton, his academic work focused on the intersection of information technology and national security issues.
VI Partners AG
Benedikt joined VI Partners in 2018 as Principal focusing on Healthcare investments. In his previous career, Benedikt build and grew a digital health start-up as COO, he provided advise as consultant of international strategy consultant firms (i.a. The Boston Consulting Group) on product development and commercial strategy to medical device and pharmaceutical companies. In addition, he served as assistant to the management of a European hospital company and focused as scientist of a university hospital on oncology research. Benedikt received a graduate (MD/ PhD) in medicine from the University of Kiel after studying medicine at the University of Kiel, University of Cape Town, Yale University and Harvard University. His PhD thesis addressed oncology/ cancer biology.
TeleMed2U’s President & CEO with oversight of corporate strategy and product development. Renard has more than 20 years of healthcare experience on facility development, operations, mergers and acquisitions and 12 years of senior executive leadership experience in the healthcare including diagnostic imaging, radiation oncology Telemedicine and Venture Capital consulting , in Profit and Non-Profit Healthcare Services Sector. Background includes CEO and executive positions to small $5 million and large publicly traded companies. Directing start-ups and turnarounds, restructuring organizations, mergers and acquisitions, raising equity and debt capital, recruiting, hiring and developing line and functional leaders. I.T implementation and planning as well as billing, and Compliance oversight . Sits on Editorial Board for Imaging Economics and has published over 60 white papers and articles trade journals. Interim General Manager for Rely TeleRadiology and Interim COO Healthcare, Vice President of Multiple Radiation and Oncology Physician Groups, Leadership positions in Diagnostic Imaging, TeleRadiology and TeleMedicine, Radiation Oncology, Mergers and Acquisitions, Private Equity, and Debt Capital, Lead five turnarounds and company restructurings. Created, opened and developed over 63 outpatient centers in Diagnostic Imaging, Surgery, Occupational Health and Physical Therapy Facilities.
Graeme Currie was most recently Vice President of Clinical Science and Operations at Dynavax Technologies Ltd. Graeme joined Dynavax in April 2016 and was a part of the team working towards approval of HEPLISAV-B and progressing the Immuno-oncology portfolio. Prior to that he spent six years at Regeneron Pharmaceuticals with the title Vice President of Clinical Project Management and Operations and oversaw all therapeutic areas, spanning 16 molecules and multiple therapeutic areas. Prior to Regeneron, Graeme was Vice President of Clinical Operations at Sepracor in Boston and at PDL Biopharma in the Bay Area. Graeme also spent 6 years as a Director at Gilead sciences working in Hepatitis and played a significant role in developing Hepsera for Chronic Hepatitis B. Prior to Gilead, he had roles at IPSEN and Glaxo Welcome, based in London and ran global programs for the development of Lanreotide for the treatment of Acromegaly and Valtrex for the treatment of HSV. Graeme received a BSc from the University of Salford in England and a PhD in Oncology from Aston University, Birmingham, England.
Big Sky Partners
Founder at Family Office Private Advisors. R. Adam Smith, combines his twenty years of experience in venture capital and private equity with a lifelong passion for unique brands. Adam held principal roles at leading private equity firms based in New York City, Caxton-Iseman Capital LLC and Castle Harlan, Inc., each with over $2 billion in managed equity capital, as well as tenures at Lehman Brothers and Salomon Brothers Inc. In 2002, he founded Circle Peak Capital (CPC), a private investment partnership. In 2010, he formed investment company Design Holdings Co LLC (DHC) to invest in a leading online global source for unique vintage furniture, antiques, art, jewelry, fashion and design. Adam graduated from the Graduate School of Business at Columbia University with an MBA with honors and from Boston University cum laude with a BA in International Relations and Economics. He is an active alumnus of Columbia Business School, a founding board member of Columbia’s Private Equity Advisory Board, and a founder of the Investment Management Conference. He is a member of hedge fund advisory company, Stride Capital. Involved in @ 20 principal investments since 1998 with over $300 million of private capital and over $2B in sales. Board member of, or Board advisor to, ten private companies. Philanthropic and non-profit ventures involving cancer, education, music, and world peace. He is one of the founders of the Friends of Leukemia Fighters, an oncology non-profit associated with the Weill Medical College of Cornell University and New York Presbyterian Hospital of New York City; chairman, Inaugural Piece for Peace Concert of the Tanenbaum Center in New York City; mentor to the Founders Institute.
Compass Therapeutics LLC
Dr. Schuetz, M.D., Ph.D., is the co-founder of Audentes Therapeutics and has served as a member of the board of directors since July 2013. Dr. Schuetz also provided consulting services to Audentes from July 2012 to June 2013. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed. Dr. Schuetz served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has also served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz also serves on the board of directors of Relypsa, Inc. and Glypharma, Inc. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.